Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT
· Real-Time Price · USD
7.55
-0.07 (-0.92%)
At close: Oct 16, 2025, 3:59 PM
7.64
1.19%
After-hours: Oct 16, 2025, 07:59 PM EDT
-0.92% (1D)
| Bid | 7.51 |
| Market Cap | 234.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.38M |
| EPS (ttm) | -1.86 |
| PE Ratio (ttm) | -4.06 |
| Forward PE | -3.87 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.64 |
| Volume | 383,259 |
| Avg. Volume (20D) | 613,618 |
| Open | 7.81 |
| Previous Close | 7.62 |
| Day's Range | 7.50 - 8.11 |
| 52-Week Range | 1.73 - 11.41 |
| Beta | 3.27 |
| Ex-Dividend Date | n/a |
About SGMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SGMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SGMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+6.36%
Sagimet Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+12.4%
Sagimet Biosciences shares are trading higher after the company announced its Phase 3 Denifanstat acne therapy clinical trial met all primary and secondary endpoints.
1 week ago · seekingalpha.com
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 ReadoutsSagimet Biosciences (SGMT) is well-positioned financially, with $135 million in cash and minimal debt, supporting operations through early 2028. SGMT's lead asset, denifanstat, is advancing in combina...
1 month ago · seekingalpha.com
Sagimet Gains Momentum As FDA Eases Path For MASH Drug DevelopmentSagimet Biosciences offers a unique play in MASH with Denifanstat, a FASN inhibitor showing both fat reduction and fibrosis regression in Phase 2b. The FDA's acceptance of non-invasive trial endpoints...
